Amplo Biotechnology is a startup based in the United Kingdom.
Amplo Biotechnology is a startup based in the United Kingdom.
Amplo Biotechnology develops AAV gene therapies targeting diseases of the neuromuscular junction, including Congenital Myasthenic Syndromes and muscular dystrophies, with their lead candidates AMP-101 and AMP-201 in preclinical and clinical trial preparation stages.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.